Cargando…
A review of ropinirole prolonged release in Parkinson’s disease
Ropinirole prolonged release is a once-daily, 24-hour formulation of ropinirole, a non-ergot dopamine agonist. It is approved as monotherapy and as an adjunct to levodopa in the treatment of Parkinson’s disease (PD). Several potential advantages of ropinirole prolonged release compared to the immedi...
Autores principales: | Nashatizadeh, Muhammad M, Lyons, Kelly E, Pahwa, Rajesh |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685238/ https://www.ncbi.nlm.nih.gov/pubmed/19503779 |
Ejemplares similares
-
Comparison of once-daily versus twice-daily combination of Ropinirole prolonged release in Parkinson’s disease
por: Yun, Ji Young, et al.
Publicado: (2013) -
Comparison of long‐term use of prolonged‐release ropinirole and immediate‐release dopamine agonists in an observational study in patients with Parkinson's disease
por: Gungabissoon, Usha, et al.
Publicado: (2020) -
Update on ropinirole in the treatment of Parkinson’s disease
por: Shill, Holly A, et al.
Publicado: (2009) -
Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease
por: Sharma, Vibhash D, et al.
Publicado: (2018) -
Sleep Duration and “on” Time during Different Periods of the Day and Night in Patients with Advanced Parkinson's Disease Receiving Adjunctive Ropinirole Prolonged Release
por: Reichmann, Heinz, et al.
Publicado: (2011)